An ongoing phase I clinical trial (NCT05501912) is evaluating the efficacy and anti-cancer activity of ABM-1310, a highly potent and selective BRAF inhibitor, in patients with BRAF V600-mutant advanced solid tumors, including CCA. This evidence concerns the gene BRAF and cholangiocarcinoma.